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Abstract 
Background: Antibody-based therapies targeting CD38 are currently used as single agents as well as in combina-
tion regimens for multiple myeloma, a malignant plasma cell disorder. In this study, we aimed to develop anti-CD38 
single-domain antibodies (sdAbs) that can be used to trace  CD38+ tumour cells and subsequently used for targeted 
radionuclide therapy. SdAbs are derived from Camelidae heavy-chain antibodies and have emerged as promising 
theranostic agents due to their favourable pharmacological properties.
Methods: Four different anti-CD38 sdAbs were produced, and their binding affinities and potential competition with 
the monoclonal antibody daratumumab were tested using biolayer interferometry. Their binding kinetics and poten-
tial cell internalisation were further studied after radiolabelling with the diagnostic radioisotope Indium-111. The 
resulting radiotracers were evaluated in vivo for their tumour-targeting potential and biodistribution through single-
photon emission computed tomography (SPECT/CT) imaging and serial dissections. Finally, therapeutic efficacy of 
a lead anti-CD38 sdAb, radiolabelled with the therapeutic radioisotope Lutetium-177, was evaluated in a  CD38+ MM 
xenograft model.
Results : We retained anti-CD38 sdAb #2F8 as lead based on its excellent affinity and superior stability, the absence 
of competition with daratumumab and the lack of receptor-mediated internalisation. When intravenously adminis-
tered to tumour-xenografted mice, radiolabelled sdAb #2F8 revealed specific and sustained tumour retention with 
low accumulation in other tissues, except kidneys, resulting in high tumour-to-normal tissue ratios. In a therapeutic 
setting, myeloma-bearing mice received three consecutive intravenous administrations of a high (18.5 MBq) or a 
low radioactive dose (9.3 MBq) of 177Lu-DTPA-2F8 or an equal volume of vehicle solution. A dose-dependent tumour 
regression was observed, which translated into a prolonged median survival from 43 days for vehicle-treated mice, 
to 62 days (p = 0.027) in mice receiving the low and 65 days in mice receiving the high (p = 0.0007) radioactive dose 
regimen, respectively.
Conclusions: These results highlight the theranostic potential of radiolabelled anti-CD38 sdAbs for the monitoring 
and treatment of multiple myeloma.
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Introduction
The field of theranostics represents the clinic’s ongo-
ing efforts to develop more specific and individualised 
therapies for various diseases and to combine diagnostic 
and therapeutic capabilities into a single pharmaceuti-
cal agent [1]. Nuclear medicine is ideally positioned to 
play a central role in theranostics. Indeed, diagnostic 
radionuclides linked to an antigen-binding vector allow 
to visualise molecular targets, to provide non-invasive 
information on biomarker expression, to select patients 
for targeted therapies and to monitor therapy responses. 
Conjugating that same vector to therapeutic radionu-
clides enables targeted radionuclide therapy (TRNT).
Immunotherapy is revolutionising the treatment of 
multiple myeloma (MM). This disease, characterised by 
the clonal proliferation of malignant plasma cells in the 
bone marrow, has a high unmet therapeutic need [2]. 
Daratumumab is the first-in-class CD38-binding mono-
clonal antibody (mAb) that is currently FDA- and EMA-
approved for monotherapy or combination therapy for 
relapsed MM, based on impressive results in large phase 
3 trials [3]. Unfortunately, not all pre-treated patients 
respond to daratumumab, and some patients who 
initially respond eventually become resistant to the treat-
ment. Although baseline CD38 levels are predictive of 
response, they are not routinely evaluated before the ini-
tiation of daratumumab treatment. Therefore, there is a 
need for theranostic agents to identify and treat patients 
who might benefit from anti-CD38-based therapies.
Different CD38-targeting agents have been integrated 
in theranostic constructs including mAbs, single-chain 
variable fragments (scFv) and single-domain antibodies 
(sdAbs) [4–7]. They were either directly or indirectly cou-
pled to diagnostic or therapeutic radionuclides, or fluo-
rochromes. Single-domain antibody fragments (sdAbs) 
are derived from Camelidae heavy-chain antibodies and 
have emerged as promising vectors [8]. Due to their small 
size, sdAbs have favourable pharmacological properties 
compared to conventional Abs or Ab fragments, includ-
ing an improved tissue penetration, a fast clearance 
from the circulation and a high conformational stability 
(Additional file 1: Fig. 1). Moreover, their straightforward 
production and engineering allow researchers to adapt 
and include them into a variety of applications [9–11]. 
Finally, their long flexible antigen-binding loops allow the 
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Fig. 1 Monoparametric representations of labelled tumour cells with APC from flow cytometry experiments. Image obtained from density plot 
(FSC/SSC) with single marker APC. a Histogram of the mean fluorescence intensity measured on RPMI cells’ surface. The red peak corresponds to 
RPMI 8226 stained with the secondary APC-labelled anti-H6 mAb alone. The blue one shows the staining of RPMI 8226 with sdAb #2F8 followed by 
the secondary Ab and the orange peak a similar staining on  CD38KO cells. b Histograms of the 2F8’s association to the surface of different cell lines 
expressing (LP1, RPMI, LB5871-LYMP (LB) or not (OPM2) the CD38 receptor. A clear binding of the sdAb #2F8 to the surface of LP1 (light green) and 
RPMI cells (yellow) is observed. SdAb #2F8 also binds to the surface of lymphoma cells, although less significantly (LB, light blue). No interactions 
were identified on the OPM2’s membrane (red peaks)
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recognition of buried epitopes, and they appear not to be 
immunogenic [12].
In this work, we describe the development of a radi-
olabelled sdAb as a theranostic agent targeting CD38 
that could ultimately predict responsiveness to and at the 
same time allow for an anti-CD38 treatment strategy.
Material and methods
Expression and purification of His‑tagged and untagged 
sdAbs
Non-targeting control sdAbs cAb-BcII10 and R3B23 were 
generated as described before [13]. To obtain the four 
hexahistidine  (His6)-tagged sdAbs (i.e. #551 [5], #375 [5], 
#1053 [5] and #2F8 [14]), their genes were cloned into the 
expression vectors pHEN2 or pHEN6 and subsequently 
transformed into the E. coli WK6 cells [15]. These His-
tagged sdAbs were purified by metal chelate affinity chro-
matography [10]. Residual imidazole was removed by gel 
filtration (Sephadex G25). A stop-codon was introduced 
by mutation before the His-tag coding region to produce 
untagged nanobodies #551 and #2F8. Untagged sdAbs 
were produced and subsequently purified by combining 
ionic exchange (high TRAP Q HP and Capto S resin) and 
size exclusion chromatography (Superdex 75) in 50 mM 
HEPES, 150 mM NaCl. The purity and integrity of sdAbs 




The specific binding of sdAbs to cells expressing CD38 
was assessed using different cancer cell lines, such as 
RPMI 8226 cells  (CD38+ or  CD38KO), LP1, K562, U266 
and LB5871-LYMP. Cells were incubated with 100  nM 
of purified  His6-tagged sdAbs for 30  min at 4  °C. After 
washing with PBS-3%FBS, the cells were incubated with a 
secondary antibody (APC-conjugated anti-His mAb, Bio-
Legend). Stained cells were analysed on a BD FACSAr-
ray™ Bioanalyzer System (BD Biosciences). An irrelevant 
non-targeting sdAb (cAb-BcII10) was used as a reference 
for non-specific binding. To study the internalisation of 
sdAb #2F8, the same cells were incubated with 10  nM 
sdAb 2F8 at 37 °C over time. At different time points dur-
ing incubation, cells were labelled with the secondary 
anti-His mAb to measure the dynamics of sdAbs bound 
to the cell membrane.
Biolayer interferometry
To assess the binding affinity by interferometry using the 
OctetHTX platform, streptavidin (SA)-coated biosensor 
tips (Pall ForteBio) were used to capture the biotinylated 
extracellular domain of the CD38. Kinetic measurements 
for sdAb binding were performed by dipping the CD38-
coated biosensors into wells containing seven different 
concentrations of the corresponding sdAbs (from 2.5 to 
50  nM), followed by a dissociation time by transferring 
the biosensors into buffer-containing wells. All sensor-
grams were referenced for buffer effects and then fitted 
using the OctetHTX user software. Kinetic responses 
were fitted to a 1:1 binding model to obtain values for 
association  (kon) and dissociation  (koff) rate constants, 
and the equilibrium dissociation constant  (KD). This 
experiment was also performed for DTPA-conjugated 
#2F8 but with four different concentrations (from 20 
to 100  nM). Competition between antibodies for CD38 
binding was assessed by dipping the CD38-coated bio-
sensors into wells containing a first antibody of interest 
(100  nM) until saturation (first association). Then, the 
sensors were immersed into a well containing the first 
and second antibodies (100  nM) (second association) 
allowing to monitor the binding capacities of the second 
antibody in the presence of the first one.
Protein stability
Circular dichroism (CD) measurements were taken with 
a 810 Jasco Spectrophotometer, either in the far UV 
(190–250 nm) or in the near UV (250–350 nm) regions, 
using a sdAb concentration of 0.2  mg/mL in 50  mM 
sodium buffer, and 0.1-cm or 1-cm pathlength quartz 
cell, respectively. Spectra were acquired at a scan speed 
of 50 nm/min, with a 1-nm bandwidth, a 2-s integration 
time and at 25  °C. Five spectrums were acquired, aver-
aged and corrected by subtracting the buffer spectrum 
recorded under identical conditions. Thermal unfold-
ing experiments were monitored at 205  nm by raising 
the temperature from 25 to 97 °C at a rate of 0.5 °C/min. 
The reversibility of the transition was assayed by cool-
ing the sample down to 25  °C. Data were acquired with 
a 4-s integration time and a 1-nm bandwidth. The heat-
induced unfolding transitions monitored were used to 
determine the mid-transition temperature  (Tm, tempera-
ture at which 50% of the protein molecules are unfolded, 
while the remaining are native) by fitting the experimen-
tal data with the equation of a two-state model [16]. Since 
the transitions were not reversible, only apparent Tm 
could be determined (Tm*).
Cell line and mouse model
The human MM cancer cell line RPMI 8226  (GFP+/Lucif-
erase+) was obtained from A. Martens (Haematology 
department, VU University Medical Center, The Nether-
lands). RPMI 8226 cells were cultured using Roswell Park 
Memorial Institute medium (RPMI 1640, Lonza, Bel-
gium) enriched with 10% foetal bovine serum, 100 U/mL 
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penicillin and 0.1 mg/mL streptomycin. K562 cells were 
purchased from ATCC (Manassas, Virginia, US), double-
hit lymphoma cell line LB5871-LYMP was obtained from 
N. Van Baren (UCL, Brussels) [17], and finally, U266, 
OPM2 and LP-1 cell lines were obtained from H. Jern-
berg-Wiklund (Uppsala University, Sweden), respectively.
The CD38 knockout (KO) cells used as specific controls 
were obtained by genetic engineering using the CRISPR/
Cas9 technique as previously described [18].
Tumour xenografts were obtained by subcutaneously 
(s.c.) inoculating 6- to 12-week-old NOD.Cg-Prkdcsci 
 Il2rgtm1Wjl1wʲˡ / SzJ (NSG) mice with RPMI 8226 cells 
(0.5 ×  106) in 150  μL PBS-Matrigel (ratio 1:1) into the 
left hind. Mice were irradiated with 2  Gy 24  h before 
cell injection to favour a homogenous tumour uptake. 
Tumour development was followed from day 14 (palpa-
ble from day 19) using an IVIS Spectrum In Vivo Imag-
ing System (PerkinElmer). Briefly, after s.c. injection 
of D-luciferin (150  mg/kg), anaesthetised mice were 
imaged (scan and reading of luminescence emitted dur-
ing substrate degradation by cancer cells expressing the 
luciferase). All animal experiments were approved by the 
Ethical Committee for Animal Experiments of the Uni-
versity of Liège and of Vrije Universiteit Brussel.
Nuclear imaging using 99mTc‑sdAbs
Anti-CD38 sdAbs were radiolabelled with 99mTc at 
their C-terminal  His6-tag using the Isolink labelling kit 
(Mallinckrodt Medical BV), as previously described 
[19]. 99mTc-sdAbs were separated from unreacted 
 [99mTc(H2O)3(CO)3]+ via NAP-5 size exclusion chro-
matography (Sephadex, GE Healthcare). The eluate was 
passed through a 0.22  μm filter (Millipore), and radio-
chemical purity (RCP) was determined by instant thin-
layer chromatography (iTLC) using acetone as running 
buffer (iTLC-SG, Pall Corporation) and was > 95%. Mice 
bearing s.c.  CD38+ RPMI 8226 tumours (n = 3) were 
intravenously (i.v.) injected with 99mTc-labelled sdAbs 
(about 4  μg and 51.1 ± 3.7  MBq). At 1  h post-injection 
(p.i.), mice were imaged using pinhole single-photon 
emission computed tomography (SPECT)/ computed 
tomography (CT) with a Vector + /CT MILabs sys-
tem [20]. Images were obtained using a rat SPECT-col-
limator (1.5-mm pinholes) in spiral mode, 7 positions 
with 128 s per position for whole-body imaging. Images 
were reconstructed with 0.4   mm3 voxels with 2 sub-
sets and 2 iterations, without post-reconstruction filter. 
For CT, a normal scan mode of two positions was used. 
Images were fused and corrected for attenuation based 
on the CT scan. Image analysis was performed using a 
Medical Image Data Examiner (AMIDE) software and 
data expressed as % injected activity per  cm3 (% IA/cm3) 
[21]. After imaging, mice were killed, and organs and tis-
sues were isolated and weighed. The radioactivity in each 
sample was measured using a Wizard2 γ-counter (Perki-
nElmer). Tracer uptake was expressed as % injected activ-
ity per gram organ (% IA/g).
Preparation of 111In‑ and 177Lu‑DTPA‑sdAbs
Untagged #2F8 and R3B23 (3  mg/mL) reconstituted in 
50  mM sodium carbonate buffer pH 8.5 were reacted 
with a tenfold molar excess of bifunctional chelator 
CHX-A’’-DTPA (Macrocyclics) for 3 h at RT, as described 
previously [22]. The conjugation reaction was quenched 
by reducing the pH of the mixture to pH 7.0. DTPA-2F8 
was purified on Superdex 75 10/300 GL (GE Healthcare) 
in 0.1  M ammonium acetate buffer pH 7.0. The neces-
sary amount of 111In (54 to 270 MBq) or 177Lu (74 MBq to 
1 GBq) was incubated for 30 min at RT or 37 °C, respec-
tively, with the DTPA-2F8 in 200 mM ammonium acetate 
pH 5. Resulting 111In- and 177Lu-DTPA-2F8 were purified 
on NAP-5 column (GE Healthcare) using 0.9% NaCl as 
eluent. In case of high radioactive labelling for preclinical 
therapy, 0.9% NaCl with 5 mg/mL ascorbic acid was used. 
The resulting radio-conjugates were filtered on 0.22  μm 
after which RCP was determined by iTLC with citric 
acid as running buffer (iTLC-SG, Pall Corporation) and 
measured > 96%.
In vitro evaluation of 111In‑DTPA‑2F8
Binding affinity and degree of internalisation of 
111In-DTPA-2F8 were evaluated as previously described 
[23]. In case of assessing binding affinity,  CD38+ RPMI 
8226 cells were incubated for 1  h at 4  °C with a serial 
dilution of 111In-DTPA-2F8 (0.1–300  nM) alone or in 
combination with a 100-fold molar excess of unlabelled 
2F8 to assess non-specific binding. Next, unbound 
sdAb was washed away, after which retained radio-
activity was measured in a γ-counter. Data were plot-
ted using GraphPad Prism software. To study the 
level of receptor-mediated internalisation, RPMI 8226 
cells were incubated for 1  h at 4  °C with 10  nM of 
111In-DTPA-2F8, alone or in combination with a 100-
fold molar excess of unlabelled #2F8 to assess unspe-
cific binding. After washing, the cells were incubated at 
37 °C up to 24 h. At different time points during incu-
bation, cells were processed to obtain the correspond-
ing dissociated, membrane-bound and internalised 
fraction, as described before [23]. All fractions were 
measured for radioactivity in a γ-counter.
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Nuclear imaging using 111In‑DTPA‑sdAbs
Mice bearing s.c.  CD38+ RPMI 8226 tumours (n = 3) 
were i.v. injected with 111In-DTPA-2F8 (about 
18.8 ± 0.1  MBq) or R3B23 and 150  mg/kg gelofusin. 
SPECT images were taken at different time points 
up to 48  h p.i. Images were obtained using the same 
scan parameters used as described for 99mTc acquisi-
tions, except for the number of positions [6] and time 
per position for the full body imaging (150  s) and 
number of iterations (6 instead of 7). After the last 
image acquisition, mice were killed and processed as 
described above. In parallel, a few animals (n = 3) were 
i.v. injected (4.5 ± 0.2  MBq) with 111In-DTPA-2F8 or 
111In-DTPA-R3B23, alone or as a co-injection with 
150 mg/kg gelofusin. They were imaged 1 h post-injec-
tion in order to evaluate the effect of gelofusin on the 
renal retention of the tracer.
Biodistribution and dosimetry 177Lu‑DTPA‑2F8
Mice bearing  CD38+ RPMI 8226 tumours were 
i.v. injected with 177Lu-DTPA-2F8 (about 4  μg and 
4.5 ± 0.2  MBq) co-infused with 150  mg/kg gelofusin 
(n = 3). Next, mice were killed at different time points 
up to 48  h p.i., followed by the isolation of differ-
ent organs and tissues. All samples were weighed and 
counted for radioactivity content against a standard of 
known radioactivity using a γ-counter and expressed 
as percentage of the injected activity per gram of tissue 
mass (% IA/g), corrected for decay. For dosimetry pur-
poses, the biodistribution data were time-integrated to 
obtain the residence time per gram tissue [22]. Briefly, 
the area under the curve between 1 and 48  h was 
made using the trapezoid integration method. Next, 
the absorbed doses were calculated using S values for 
177Lu obtained from RADAR phantoms (Unit Density 
Spheres).
Targeted radionuclide therapy using 177Lu‑DTPA‑2F8
Day 23 post-cell inoculation, mice with palpable  CD38+ 
RPMI 8226 tumours were randomly categorised into 
three treatment groups (n = 10). Mice received three 
consecutive i.v. administrations, once every two days, of 
either: (i) a high radioactive dose (about 18.5 ± 0.5 MBq), 
(ii) a low radioactive dose (9.3 ± 0.3  MBq) 177Lu-DTPA-
2F8 + 150  mg/kg gelofusin, or (iii) an equal volume of 
vehicle solution (PBS). Animals were followed up over 
time through body condition scoring (weight, physical 
appearance, mobility and behaviour), and tumour vol-
ume was assessed via calliper measurements and biolu-
minescence imaging as described above.
Results
In vitro characterisation of sdAbs
Flow cytometry experiments revealed the specific bind-
ing of the different anti-CD38 sdAbs. Indeed, all of them 
are capable of binding the CD38 antigen on MM cell lines 
(RPMI 8226 and LP1) and non-Hodgkin’s lymphoma cells 
(LB5871-LYMP), while no specific binding was observed 
on the  CD38− cells (K562 cell line) and  CD38KO cell lines 
(Fig. 1). Non-targeting cAb-BcII10 did not show specific 
binding to CD38. 2F8 binds CD38 with an affinity in the 
low  (KD 1.5 nM) nanomolar range as illustrated in Fig. 2. 
Apparent midpoint of the heat-induced unfolding (Tm*), 
ranged from 69 to 89  °C, were obtained for the studied 
sdAbs with the #2F8 protein showing the highest one 
(88.7 ± 0.3  °C). To determine potential competition for 
CD38 targeting between daratumumab and the different 
sdAbs, competitive biolayer interferometry (BLI) experi-
ments were performed. Different levels of competition 
with daratumumab were defined: total, partial or null. No 
binding of sdAbs #1053 or #375 was detected on CD38 
that was pre-incubated with daratumumab, and vice 
versa. In contrast, sdAb #2F8 still bound in full capac-
ity, and sdAb #551 in part, to the extracellular domain of 
CD38 in the presence of daratumumab (Fig. 2). The set of 
data acquired for the other three sdAbs are summarised 
in Table 1.
Biodistribution of 99mTc ‑labelled sdAbs
The biodistribution and tumour-targeting potential of 
different 99mTc-labelled sdAbs were assessed via pin-
hole μSPECT/CT imaging and dissection. The result-
ing uptake values in tumours and non-target organs are 
summarised in Table 1. Administration of 99mTc-H6-2F8 
revealed a tumour uptake of 2.22 ± 0.47% IA/g compared 
to only 0.79 ± 0.11% IA/g for 99mTc-H6-cAb-BCII10, with 
good contrasts observed early after tracer administration 
(Fig.  3). In addition, 99mTc-H6-2F8 was found concen-
trated in kidneys and bladder, in line with the fast blood 
clearance of sdAbs [24]. Only low amounts of radioac-
tivity were measured in blood (0.39 ± 0.09% IA/g) and 
non-targeted organs and tissues (from 0.02 ± 0.01 to 
0.53 ± 0.12% IA/g) (Additional file 1: Table 1).
Saturation binding and degree of internalisation 
of 111In‑labelled sdAb 2F8
Based on the superior in  vitro and in  vivo charac-
teristics, sdAb #2F8 was selected as lead CD38-tar-
geting compound (Table  1). Untagged #2F8 was 
conjugated to p-SCN-Bn-CHX-A”-DTPA and was shown 
to maintain its binding characteristics as determined 
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Fig. 2 a (i) Biolayer interferometry sensorgrams from a dilution series of sdAb #2F8 from 50 to 2.5 nM to assess its binding to the CD38. The blue 
curves represent the experimental kinetics, and the red ones represent fit curves. (ii) Summary of the different binding parameters for the sdAbs 
studied and the sdAb 2F8 conjugated to the chelator DTPA used in radiolabelling with 111In and 177Lu. The data are expressed as mean ± SD 
(n = 4). b (i) Competitive binding between daratumumab and sdAbs (#2F8, #551, #375 or #1053) for binding to the CD38, (ii) data obtained for 
competitor sdAb #1053 and daratumumab, where no additional signal is observed upon addition of sdAb on mAb-CD38 complex (dark green) and 
vice versa (light green), (iii) similar results obtained for the sdAb #375 (addition of sdAb on mAb-CD38 complex in black and the reverse in grey), 
(iv) partial-competitor sdAb #551 and daratumumab where an additional signal is observed upon the addition of mAb on sdAb-CD38 complex 
but with a lower amplitude than when it was immobilised first (light blue). A decrease in signal after addition of sdAb on mAb-CD38 complex is 
observed (dark blue), which may indicate loss of binding for daratumumab. Finally, (v) non-competitor sdAb #2F8 and daratumumab, where no 
competition is observed. The two proteins are able to bind the receptor without impacting the signal amplitude, regardless of the order of addition
Table 1 Summary of in vitro and in vivo characterisation of the different anti-CD38 sdAbs. The affinities and competition behaviour 
towards the human monoclonal antibody daratumumab were obtained by the biolayer interferometry method
All the sdAbs have an affinity in the nanomolar range. #375 and #1053 are in competition with daratumumab, while a partial and no competition are observed 
for #551 and #2F8, respectively. The data included in the biodistribution section correspond to the results obtained after radiolabelling of sdAbs with the 99mTc 
radioisotope (Fig. 3); #551 and #2F8 show the best tumour uptake. The thermal stability (Tm*) of the sdAbs was evaluated by far UV circular dichroism. The most stable 
is #2F8. Based on these characteristics, sdAb 2F8 was chosen for further work. (ND: not-determined, protein not studied in vivo because its in vitro behaviour is similar 
to that of sdAb 1053)
Parameters sdAbs #375 #1053 #551 #2F8
Affinity  (KD) 1.49 nm 1.7 nM 1.50 nM 1.48 nM
Competition Vs daratumumab Competitor Competitor Partial competitor Non-competitor
Biodistribution
 Location ND 1.78 ± 0.37 3.37 ± 0.38 2.22 ± 0.47
 Tumour ND 258.00 ± 19.08 402.20 ± 22.46 169.32 ± 4.56
 Blood ND 0.61 ± 0.26 1.33 ± 0.08 0.53 ± 0.12
 Liver ND 1.28 ± 0.28 1.33 ± 0.08 0.53 ± 0.12
 Thermal stability (Tm*) 69.1 ± 0.1 °C 73.1 ± 0.1 °C 72.2 ± 0.2 °C 88.7 ± 0.3 °C
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Fig. 3 a Ex vivo biodistribution of 99mTc-labelled sdAbs in RPMI 8226  CD38+ tumour-bearing mice based on dissection data at 1 h p.i. and 
expressed as % IA/g (data from these results are included in Additional file 1: Table 1). b In vivo biodistribution of the radiolabelled sdAbs injected 
in mice expressed as % IA/cc. Data shown in Additional file 1: Table 3. Data are mean ± standard deviation of three mice/sdAb. A radiolabelled 
irrelevant non-targeting sdAb was used as negative control. c Sagittal and transversal view on fused whole-body and tumour-focused μSPECT/
CT acquisitions 1 h p.i. of intravenously injected 99mTc-H6-2F8, 
99mTc-H6-1053, 
99mTc-H6-551 and non-targeting 
99mTc-H6-CTRL in MM mice. One 
representative of each group is shown. Green arrows indicate tumour uptake, while the yellow and pink arrows indicate renal and urinary bladder 
uptake, respectively. NIH + white colour scale is used, and images are normalised to the activity at the time of acquisition and equally scaled down 
to 4% relative to maximum activity in image. For all CD38 sdAbs, the following observation can be made: a non-specific uptake by the kidneys, 
a tumour site-specific accumulation and a background radioactivity level in most vital organs, albeit at different levels depending on the sdAb. 
Tumour-to-organ ratios were calculated and are described in Additional file 1: Table 2
(See figure on next page.)
Fig. 4 a Saturation binding curve of 111In-DTPA-2F8 on RPMI 8226 cells. The maximal effective concentration  (EC50) was calculated by subtracting 
non-specific-bound activity (assessed by adding an excess of unlabelled sdAb) from total bound activity and plotted in function of 111In-sdAb 
concentrations. Data are expressed as mean ± SD. b Ex vivo biodistribution of 111In-DTPA- 2F8 or R3B23 sdAbs. NOD scid gamma mice (n = 3) 
bearing RPMI 8226 tumour  (105 cells injected subcutaneously in the left side) were injected at -1 h with 4.5 ± 0.2 MBq of radiolabelled sdAb 
and euthanised for organ harvesting. Data displayed on the bar graph are expressed as % IA/g and detailed in Additional file 1: Table 4. 
c Cell-internalisation assays using sdAb #2F8. (i) Plot representing the internalised fraction of 111In-radiolabelled sdAb #2F8 over time, (ii) 
membrane-bound fraction of APC-anti-Histag-2F8 over time, assessed via flow cytometry. d In vivo biodistribution of 111In-labelled sdAb #2F8 
(18.8 ± 0.1 MBq) + 150 mg/kg gelofusin for a selection of organs and tissues up to 48 h p.i. e Biodistribution of 111In-labelled sdAb #2F8 and the 
non-targeting sdAb after 1 and 48 h post-tracer administration (18.8 ± 0.1 MBq). Both are co-injected with 150 mg/kg gelofusin. Data are presented 
as mean ± SD (n = 3) and further detailed in Additional file 1: Tables 5 and 6. Images illustrating these biodistributions are included in Additional 
file 1: Fig. 2
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Fig. 4 (See legend on previous page.)
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with radioactivity and BLI experiments (Figs.  2 and 4). 
After radiolabelling with 111In, both the maximal effective 
concentration  (EC50) and the level of internalisation were 
assessed on RPMI 8226 cells.  EC50 for 111In-DTPA-2F8 
measured 16.7 ± 3.2 nM. 111In-DPTA-2F8 bound well to 
CD38 + RPMI 8226 cells but did not induce receptor-
mediated internalisation, as this fraction remained low at 
all time points until 24 h (Fig. 4, panel Ci). Flow cytom-
etry confirmed the minor internalisation of sdAb #2F8 
(Fig. 4, panel Cii).
Biodistribution of 111In‑ and 177Lu ‑labelled sdAb 2F8
Mice bearing  CD38+ RPMI 8226 tumours were i.v. 
injected with either 111In-DPTA-2F8 alone, 111In-DPTA-
2F8 in combination with 150  mg/kg gelofusin or 
111In-DTPA-R3B23. 111In-DPTA-2F8 showed high 
and specific uptake in tumour 1  h after tracer injec-
tion. High levels of radioactivity were observed in kid-
neys (23.00 ± 2.62% IA/g) after 1  h, which was reduced 
by co-injection with 150  mg/kg gelofusin to only 
13.00 ± 0.02% IA/g Fig. 4B and Additional file 1: Table 4. 
111In-DTPA-R3B23 revealed no relevant uptake in 
tumour (0.54 ± 0.14% IA/g), while the amount in kidneys 
was similar. Uptake of CD38-specific sdAbs in all other 
organs and tissues was low and considered as background 
(Fig. 4). A head-to-head comparison of uptake in tumour 
and kidneys between 99mTc-H6-tagged-2F8, 111In- and 
177Lu-labelled untagged-2F8 is depicted in Fig.  5B. 
Removal of the hexahistidine tag and co-infusion with 
150 mg/kg gelofusin reduced kidney retention by 86 and 
57%, respectively. Uptake in tumour of 177Lu-DTPA-2F8 
co-injected with 150  mg/kg gelofusin measured about 
4.5% IA/g and remained constant over time up to 48  h 
p.i. (Fig.  5A). The renal uptake peaked at 18% IA/g 1  h 
after administration and decreased to 2% IA/g at 24 h p.i. 
and about 1.2% IA/g at 48 h p.i. The uptake values over 
time for different organs and tissues were used for dosim-
etry calculations. Both tumour and kidneys received the 
highest absorbed doses per unit of activity, with values of 
0.1 and 0.22 Gy per MBq of 177Lu-DTPA-2F8 (Additional 
file 1: Table 7). Absorbed doses to additional organs and 
tissues measured below 0.006 Gy per MBq.
Therapeutic efficacy of 177Lu‑DTPA‑2F8
Therapeutic efficacy of 177Lu-DTPA-2F8 was assessed in 
mice bearing  CD38+ RPMI 8226 tumours. Mice received 
three i.v. injections of either high radioactive dose 
(18.5 ± 0.5 MBq) or low radioactive dose (9.3 ± 0.3 MBq) 
regimen of 177Lu-DTPA-2F8, or an equal volume of vehi-
cle solution, which led to cumulative absorbed doses 
to kidneys and tumour of 6.21 and 2.77  Gy, and 12.31 
and 5.50 Gy for the low- and high-dose groups, respec-
tively. Figure  6A illustrates tumour volume evolution 
for all three treatment groups. The direct comparison 
of tumour volumes at day 43 after tumour inoculation 
revealed a dose-dependent tumour reduction for both 
Fig. 5 a Time-dependent biodistribution of 177Lu-DTPA-2F8 i.v. co-injected with gelofusin 150 mg/kg into RPMI 8226  CD38+ tumour-bearing mice 
 (105 cells injected subcutaneously in the left back side). Values are represented as % IA/g, obtained after dissection and further detailed in Additional 
file 1: Table 7. Data are presented as mean ± SD (n = 3). b Comparison of renal and tumour retention observed for #2F8 labelled with different 
radioisotopes (n = 3), alone or with 150 mg/kg gelofusin. Data are expressed as mean ± SD
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dose regimens compared to vehicle solution (Fig.  6C). 
These changes were confirmed by similar reduction in 
tumour burden, quantified by bioluminescence (not 
shown). The median survival (Fig. 6B) of vehicle-treated 
mice was 43 days, compared to 62 days for the low radio-
active dose regimen (p = 0.027) and 65 days for the high 
radioactive dose regimen (p = 0.0007).
Discussion
The results presented herein highlight the theranostic 
potential of radiolabelled CD38-targeting sdAb #2F8 for 
MM. The radiolabelling of antibodies or Ab-fragments 
and their subsequent use for nuclear imaging is an attrac-
tive tool that helps to assess tumour target expression 
and distribution in a non-invasive manner. This field of 
Fig. 6 TRNT using 177Lu-labelled sdAb 2F8. a Tumour volumes  (cm3) for mice as a function of time (days post-injection), data are expressed as 
mean ± SD (graph showing the mice individually is presented in Additional file 1: Fig. 3). b Resulting survival curves of the different treatment 
groups (n = 10, tumour inoculation on day 20). Mice injected with vehicle reached tumours > 1  cm3 between 21 and 47 days (based on individual 
analyses). Animals treated with three radioactive doses of 9.3 MBq 177Lu-DTPA-sdAb 2F8 had tumours exceeding 1  cm3 from day 28 onwards, 
resulting in a median survival of 62 days post-MM cancer cell inoculation. Animals receiving 18.5 MBq 177Lu-DTPA-2F8 three times surpassed a 
tumour size > 1  cm3 from 50 days onwards, and survival was significantly longer (p < 0.0002, log-rank Mantel–Cox test) with a median survival 
of 65.5 days. Median survival in both groups receiving 177Lu-DTPA-2F8 was significantly longer than that for animals receiving vehicle solution (* 
p < 0.0332, *** p < 0.0002, log-rank Mantel–Cox test). c Tumour size comparison at day 23 post-first treatment (or day 43 post-inoculation of MM 
cancer cells). Data shown are mean ± SD. (ns: not significant, ** p < 0.005, using one-way ANOVA, Tukey’s multiple comparison test). d Weight 
progression of the different treated groups. Data are expressed as mean ± SD
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nuclear medicine is dramatically expanding by incorpo-
rating new conjugation strategies, radiochemistry proce-
dures and Ab fragments or mimetics. SdAbs, which are 
the variable binding domains of  heavy-chain antibodies, 
have favourable properties as observed for sdAb #2F8: 
they have a low molecular weight of about 12–15 kDa and 
a straightforward recombinant production in different 
hosts; moreover, they can be easily conjugated with diag-
nostic or therapeutic isotopes using standardised radiola-
belling procedures without affecting protein affinity for 
its antigen and thus its targeting potential.Camelidae
SdAb #2F8 was chosen based on its favourable bio-
distribution with a good tumour uptake, the absence of 
competition with daratumumab and the lack of receptor-
mediated internalisation. Another CD38-binding sdAb, 
#1053, was recently conjugated to 68  Ga and developed 
as an imaging probe [25]. Our results indicate that #1053 
competes with daratumumab for binding to CD38 and 
the seminal work of the group of Koch-Nolte showed 
that both bind to the same epitope [26].
In contrast to daratumumab, which induces an inter-
nalisation of the antigen–antibody complex and a fur-
ther downregulation of CD38 expression on the MM cell 
[27, 28], sdAb #2F8 is minimally internalised after CD38 
binding. The absence of internalisation is an important 
feature allowing the realisation of a diagnostic immune-
PET (positron emission tomography) before a CD38-tar-
geting therapeutic counterpart is given without fearing a 
reduced antigen expression due to the diagnostic inter-
vention. In addition, as a therapeutic compound, #2F8 
can be administrated repeatedly without affecting CD38 
expression. The prolonged localisation of #2F8 on the cell 
membrane favours other therapeutic applications such 
as pretargeting systems that are based on the separation 
between the administration of the targeting molecule 
and the radiolabelled agent [29]. The strong binding, 
long tumour retention and persistence of its extracellular 
localisation make this sdAb interesting for further inte-
gration in such pretargeting system.
Other vectors targeting CD38 have been reported, 
with a few strategies already evaluated in the clinic [30, 
31]. Except for one bispecific construct, all use full-size 
mAbs as vector. mAbs are known to have a long blood 
circulation time and slow accumulation in target tissues 
which requires to wait days after tracer administration 
before appropriate image contrast is achieved (for dara-
tumumab, the ideal scanning time is between days 5 and 
8) [30]. The fast and specific targeting potential of sdAbs 
in combination with the fast clearance of the unbound 
fraction in the kidneys (half-time about 20  min) allows 
for a same-day imaging approach, much like the current 
practice for 18F-FDG-PET [32–34]. While their reduced 
size favours fast clearance, the biodistribution studies 
presented herein indicate, however, a high kidney reten-
tion as observed with other sdAbs, peptides or scaffold 
proteins [35]. This high retention can be explained by 
their glomerular filtration followed by tubular reabsorp-
tion and subsequent lysosomal degradation [35]. Strat-
egies for kidney protection that have been proposed 
include the infusion of positively charged basic amino 
acids  or gelofusin  []. In the presented study, the co-
injection of radiolabelled 2F8 with gelofusin decreased 
renal uptake by 57%.24, 36
In addition to the diagnostic capacities, #2F8 was 
also successfully evaluated in the framework of TRNT. 
Indeed, repeated administration of #2F8, coupled to 
the β−-particle emitting radionuclide 177Lu, resulted in 
a significant decrease in tumour burden and in a pro-
longed survival of MM-diseased mice. These responses 
were dose-dependent with a strong reduction with the 
high radioactive dose regimen. Repeating low radioac-
tive doses resulted in a similar improvement in survival. 
This treatment strategy was chosen to mimic a clini-
cal approach of fractionated dosing to lower the toxicity 
on the surrounding healthy tissues, as used for peptide 
receptor radionuclide therapy with 177Lu-DOTATATE 
[37].
The group of D. Green and O. Press was the first to 
develop a CD38-based TRNT approach [38]. Both a 
classical approach using a directly radiolabelled murine 
anti-CD38 mAb and a more innovative pretargeting 
approach were assessed. In the first pretargeting study, 
an antibody-SA construct was combined with a radiola-
belled biotin [38]. This pretargeting system improved 
the radioactivity deposition in organs and tissues and 
delayed tumour development in a therapeutic setting 
[38]. In a second pretargeting study, the scFv of an anti-
CD38 mAb and a scFV conjugated to Yttrium-DOTA 
ligand were merged in a bispecific Ab fusion protein [7]. 
This bispecific Ab showed better anti-tumour effects 
compared to the SA-biotin system when administered 
to  CD38+ tumour-bearing mice. Lastly, an anti-CD38 
mAb was radiolabelled with the alpha-particle emitting 
radionuclide Astatine-211 (211At), which also showed to 
delay tumour growth in MM models with subcutaneous 
tumours or with minimal residual disease. Other alpha-
particle emitters (212Pb, 225Ac and 213Bi) have been evalu-
ated in the framework of CD38-based TRNT and most 
indicated strong anti-tumour effects [39–41]. One study 
directly compared the efficacy of mAbs labelled with the 
α-particle emitting 225Ac or with the β−-particle emitting 
177Lu and found a higher efficacy and less toxicity for the 
225Ac-labelled variant (42).
Radiolabelled sdAbs are promising theranostic vehi-
cles to follow up disease relapse and to treat dissemi-
nated disease. The results presented herein highlight 
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the potential of radiolabelled #2F8 to target CD38 
expressing MM lesions. Radiolabelled with diagnos-
tic radioisotopes such as 99mTc and 111In, #2F8 targets 
CD38 receptor in a fast and specific manner, allowing 
high-contrast SPECT images early after tracer adminis-
tration. Repeated administration of 177Lu-labelled #2F8 
extends survival of mice significantly compared to con-
trols and in a dose-dependent manner.
Conclusion
In this study, we identified a new anti-CD38 sdAb frag-
ment that recognises another epitope as the mAb dara-
tumumab and that is not internalised after binding to 
CD38. This lead sdAb 2F8 had a favourable biodistri-
bution and was successfully integrated in a therapeutic 
radio-immunoconjugate that delayed tumour progres-
sion and prolonged survival of MM xenografts. Taken 
together, these results highlight the theranostic poten-
tial of our lead sdAb and its relevance towards clinical 
translation.
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